Study to investigate safety and tolerability of a single dose of AZD6482
Study identifier:D1700C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, double-blind, placebo-controlled Phase I study to assess the tolerability, safety, pharmacokinetic, and pharmacodynamic properties of AZD6482, alone and co-administered with ASA, after single ascending intravenous doses to healthy male subjects
Medical condition
Antiplatelet effect
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6482, Placebo
Sex
Male
Actual Enrollment
49
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Jan 2008
Primary Completion Date: 01 May 2008
Study Completion Date: 01 May 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD6482 0,9-364,5 mg administrated through intravenous infusion over 3 hours |
| Placebo Comparator: 2 | - |
Contacts
Investigators
Principal Investigator
Marianne Hartford
AstraZeneca R&D, Clinical Pharmacology Unit, Sahlgrenska University Hospital, Göteborg, Sweden
